Vikas Goyal has been working in the biotech industry for 20 years, with a particular focus on corporate strategy, capital formation, corporate partnerships, and M&A for early stage therapeutics companies.
Vikas is a Partner at Longwood Fund where he focuses on growth stage investments in late preclinical and clinical stage biotechnology companies. Prior to joining Longwood Fund, Vikas was a Managing Partner at Trekk Venture Partners, where he led investments in biotechnology companies developing life-changing medicines. Previously, Vikas was Senior Vice President of Business Development for Pandion Therapeutics. He initially joined Pandion as a Board member and investor in 2018, and ultimately joined the company full-time in 2019 taking the company through a research collaboration with Astellas, an IPO, and the company’s acquisition by Merck for $1.85 billion in 2021. Vikas joined Pandion from SR One, where he invested in and served on the boards of 19 early stage biotech companies including Morphic Therapeutics (acquired by Eli Lilly), River Vision Development (acquired by Horizon), Nimbus Therapeutics (Tyk2 acquired by Takeda), Spero Therapeutics (tebipenem acquired by GSK) and Pandion (acquired by Merck). River Vision and Horizon developed Tepezza™ (teprotumumab) a new standard of care in the treatment of Grave’s Orbitopathy and the first therapy ever approved for the indication.
Earlier in his career, Vikas was a Consultant at McKinsey & Co’s Pharmaceutical practice in New Jersey, a co-founder of Extera Partners, and a Business Development Manager at Infinity Pharmaceuticals. He is a member of the Kauffman Fellows Society (Class 17). Vikas earned an MBA in Health Care Management from the Wharton School of the University of Pennsylvania and a BA in Neurobiology from Harvard University. He is a board member of the Wharton Health Care Alumni Association.
